Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ICCC 
ImmuCell Corporation (ICCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: ICCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.6% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.73M USD | Price to earnings Ratio 28.81 | 1Y Target Price 14 |
Price to earnings Ratio 28.81 | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.19 | 52 Weeks Range 4.28 - 7.60 | Updated Date 11/22/2025 |
52 Weeks Range 4.28 - 7.60 | Updated Date 11/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When After Market | Estimate - | Actual -0.02 |
Profitability
Profit Margin 6.23% | Operating Margin (TTM) 8.84% |
Management Effectiveness
Return on Assets (TTM) 3.02% | Return on Equity (TTM) 6.61% |
Valuation
Trailing PE 28.81 | Forward PE - | Enterprise Value 57210191 | Price to Sales(TTM) 1.84 |
Enterprise Value 57210191 | Price to Sales(TTM) 1.84 | ||
Enterprise Value to Revenue 2.07 | Enterprise Value to EBITDA 10.46 | Shares Outstanding 9045851 | Shares Floating 6016396 |
Shares Outstanding 9045851 | Shares Floating 6016396 | ||
Percent Insiders 27.89 | Percent Institutions 19.95 |
Upturn AI SWOT
ImmuCell Corporation
Company Overview
History and Background
ImmuCell Corporation was founded in 1982 and is focused on developing, manufacturing, and marketing products that improve the health and productivity of dairy and beef cattle. Initially focused on antibody-based products, they have evolved to include novel solutions for animal health.
Core Business Areas
- First Defense: This segment focuses on colostrum management for newborn calves, providing passive immunity through antibody-rich products. Key products include boluses and liquid formulations.
- Re-Tain: Re-Tain is designed to treat subclinical mastitis in dairy cows and help lower somatic cell counts. The drug is a non-antibiotic solution.
- Pipeline Products: Focuses on developing new products targeting bovine health issues. The pipeline includes investigational products and future products.
Leadership and Structure
Michael F. Brigham is the President and CEO. The company operates with a structure focused on research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- First Defense: First Defense provides passive immunity to newborn calves. ImmuCell estimates they have roughly 25% of the market for colostrum replacement and supplementation products. Key competitors include companies like Land O' Lakes and numerous private label colostrum supplements.
- Re-Tain: Re-Tain treats subclinical mastitis. The competitive landscape includes traditional antibiotic treatments for mastitis, as well as other non-antibiotic solutions. Market share data specific to Re-Tain is less readily available, as it represents a newer category of mastitis treatment.
Market Dynamics
Industry Overview
The animal health industry is growing, driven by increasing demand for animal protein and a focus on preventative care. The dairy and beef cattle segments are particularly important, with a focus on improving animal health and productivity.
Positioning
ImmuCell is positioned as a leader in providing innovative, non-antibiotic solutions for bovine health. Their focus on preventative care and reducing antibiotic use differentiates them from some competitors.
Total Addressable Market (TAM)
The TAM for bovine health products is estimated to be in the billions of dollars. ImmuCell targets specific segments within this market, focusing on colostrum management and mastitis treatment. Their positioning allows them to capture a growing share of this market as demand for non-antibiotic alternatives increases.
Upturn SWOT Analysis
Strengths
- Specialized focus on bovine health
- Innovative non-antibiotic solutions
- Established brand recognition
- Strong customer relationships
Weaknesses
- Reliance on a limited number of products
- Smaller size compared to major animal health companies
- Susceptibility to regulatory changes
- Dependence on single manufacturing facility
Opportunities
- Expanding product line
- Entering new geographic markets
- Acquiring complementary businesses
- Capitalizing on growing demand for non-antibiotic solutions
Threats
- Competition from larger animal health companies
- Changes in regulatory requirements
- Economic downturn affecting farm incomes
- Emergence of new diseases or health challenges in cattle
Competitors and Market Share
Key Competitors
- MRK
- ELAN
- VET
Competitive Landscape
ImmuCell's advantage lies in its focus on non-antibiotic solutions and its established brand in the bovine health market. However, it faces competition from larger companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would need to be analyzed based on financial data. Without real-time data, this cannot be performed.
Future Projections: Future projections would be based on analyst estimates, which would need to be pulled from financial databases.
Recent Initiatives: Recent initiatives include expansion of the Re-Tain product line and ongoing research and development of new products.
Summary
ImmuCell Corporation is a relatively small but focused player in the bovine health market. Its strength lies in its non-antibiotic solutions and brand recognition. However, its limited product line and smaller size compared to competitors pose challenges. The company needs to expand its product portfolio and market reach to sustain growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- ImmuCell Corporation's website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ImmuCell Corporation
Exchange NASDAQ | Headquaters Portland, ME, United States | ||
IPO Launch date 1987-04-30 | Special Advisor to the CEO & Director Mr. Michael F. Brigham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | Website https://immucell.com |
Full time employees 77 | Website https://immucell.com | ||
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.